Travere Therapeutics Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. | Melinta Therapeutics Melinta Therapeutics is an antibiotics-focused company that develops and commercializes antibiotics to overcome drug-resistant infections.
| GBT (Global Blood Therapeutics) GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. | ||
Founding Date | Founding Date 2006 | Founding Date 2011 | Founding Date 2000 | Founding Date 2012 |
Type | Type Private | Type Public | Type Private | Type Public |
Tags | ||||
Locations | Locations Corsham, GB HQ | Locations San Diego, US HQ Dublin, IE | Locations Morristown, US HQ New Haven, US | Locations South San Francisco, US HQ Paris, FR Berlin, DE Baar, CH London, GB |
Employees | Employees 961% increase | Employees 46293% increase | Employees 1541% decrease | Employees 352106% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.4 b | Valuation ($) N/A | Valuation ($) 4.4 b |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $145.2m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $194.7m (FY, 2021) |
Cost of goods | Cost of goods N/A | Cost of goods $11.5m (FY, 2023) | Cost of goods N/A | Cost of goods $3.3m (FY, 2021) |
Net income | Net income N/A | Net income ($111.4m) (FY, 2023) | Net income N/A | Net income ($303.1m) (FY, 2021) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 25m | Total funding raised $ 519.2m | Total funding raised $ 88.7m |